The evaluation of the effect of brewed chicory leaf consumption in patients with non-alcoholic fatty liver disease
- Conditions
- non-alcoholic fatty liver disease.Other diseases of liver
- Registration Number
- IRCT20190819044565N2
- Lead Sponsor
- Oroumia University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Grade 2 and 3 non-alcoholic fatty liver disease through observation of steatosis in ultrasound
Older than 18 years
Interested in attending in study that filled out an informed consent form
Mental, emotional, cognitive and mental disorders
Grade 1 non-alcoholic fatty liver disease
alcohol consumption
Hepatitis B, Hepatitis C, Autoimmune Hepatitis, Liver Cancer, Cholestatic Liver Disease
Rheumatoid arthritis and other acute inflammatory diseases
Taking non-steroidal anti-inflammatory drugs, cholesterol-lowering drugs to control blood pressure such as statins, phenytoin, karmabazepine and barbiturates such as phenobarbital
Alpha-1 antitrypsin deficiency
Pancreatitis
Heart failure
Bone diseases
Coeliac disease
Supplement of Vitamin, Antioxidant, Fiber and Omega 3
Do not regularly use of brewed chicory leaf during the study
Use of anticoagulants
Hepatotoxic drugs
Hereditary hemochromatosis
Wilson's disease
Pregnant women
Lactating women
Use of contraceptives drugs
liver transplant
kidney diseases
Changes in the level of physical activity during the study
Diabetes Mellitus
Hypothyroidism
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.